Bausch + Lomb Reports Q3 Growth and Raises Guidance Under Interim CEO Appio

1. 18:11
   Acuité

   Bausch + Lomb Reports 7% Revenue Growth in Q3 2026 with Net Profit Turnaround

   Bausch + Lomb reported a 7% increase in third-quarter 2026 revenue, reaching $1.375 billion compared to $1.281 billion in the same period of 2025. The company posted a net profit of $32 million, reversing a net loss of $28 million from the previous year. Adjusted EBITDA rose to $325 million from $243 million, while operating cash flow increased to $233 million from $137 million. Segment performance showed Vision Care revenue growing 5% to $774 million, Surgical rising 9% to $234 million, and Pharmaceuticals increasing 11% to $367 million. Specific product lines contributed significantly: Miebo sales jumped 42% to $119 million, Lumify grew 35%, daily silicone-hydrogel lenses advanced 24%, and premium intraocular implants saw approximately 70% growth. For the first nine months of 2026, total revenue reached $4.013 billion, up 9% year-over-year, prompting an upward revision of full-year 2026 revenue guidance.

2. 12:27
   Vision Monday — Business

   Bausch + Lomb Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance

   Global eye health company Bausch + Lomb Corporation reported third-quarter 2026 financial results, generating $1.375 billion in total revenue, a 7 percent increase from $1.281 billion in Q3 2025. Excluding unfavorable foreign exchange impacts of $6 million, constant currency revenue rose approximately 8 percent. Growth occurred across all three segments: Vision Care increased 5 percent (6 percent constant currency), Surgical grew 9 percent, and Pharmaceuticals rose 11 percent. Key drivers included daily SiHy contact lenses, Lumify, premium IOLs, and Miebo. Operating income reached $155 million, up from $95 million the prior year. The company raised its full-year 2026 revenue guidance to $5.45–$5.55 billion from $5.44–$5.54 billion.

1. 21:00
   Optical Prism

   Bausch + Lomb Appoints Thomas J. Appio as Interim CEO; Expects to Raise 2026 Guidance

   Bausch + Lomb and parent company Bausch Health announced the appointment of Thomas J. Appio as interim chief executive officer, effective immediately. Appio, who has served as Bausch Health CEO since 2022 and was appointed chairman of the Bausch + Lomb Board in August 2026, will continue leading Bausch Health while assuming this role. Brent Saunders, CEO since 2023, departed following a mutual agreement with the Board. Based on preliminary third-quarter results, both companies expect to raise full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D. Specific details regarding the updated financial outlook will be provided when the companies report their third-quarter results on October 28, 2026.

1. 21:57
   Vision Monday — Business

   Bausch + Lomb Names Thomas J. Appio Interim CEO Following Brent Saunders' Departure

   Bausch + Lomb Corporation announced that Thomas J. Appio, chairman of its board and CEO of parent company Bausch Health, has been appointed interim CEO effective immediately. This follows the mutual agreement for Brent Saunders to depart his role as CEO, a position he held since 2023; no reason for the departure was disclosed. Appio will continue serving as Bausch Health CEO while leading Bausch + Lomb. The board cited Appio’s deep business knowledge and global leadership experience as key factors in the appointment. Separately, based on preliminary third-quarter results, both companies expect to raise full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D. Detailed financial results are scheduled for release on October 28, 2026, following the current blackout period.

2. 12:00
   Contact Lens Spectrum

   Bausch + Lomb Appoints Thomas J. Appio as Interim CEO Following Brent Saunders' Departure

   Bausch + Lomb announced that Brent Saunders stepped down as CEO effective October 12, 2026, with Thomas J. Appio appointed as interim CEO. The company stated the departure was mutually agreed upon by Saunders and the board, though no reason was disclosed. Appio, who became chairman of Bausch + Lomb’s board in August 2026, will continue serving as CEO of parent company Bausch Health, a role he has held since 2022. He previously served in leadership roles at Bausch + Lomb, including president of its international business. Saunders had led Bausch + Lomb since 2023, marking his second tenure after serving from 2010 to 2013. Prior to this, he was CEO of Allergan until its acquisition by AbbVie in 2020.

Current coverage 3·Comparable peak 18（10-29 19:00）·Comparable change over 24 hours -73%

Trends compare continuously observed participants only; coverage may be narrower than the current total. Point, click or use arrow keys to inspect hourly values.